These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 23843952)

  • 1. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
    Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
    PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Zhou H; Han W; Zhang S
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
    Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
    N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
    Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
    Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
    Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
    Naismith RT; Piccio L; Lyons JA; Lauber J; Tutlam NT; Parks BJ; Trinkaus K; Song SK; Cross AH
    Neurology; 2010 Jun; 74(23):1860-7. PubMed ID: 20530322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
    Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    Alcalá C; Gascón F; Pérez-Miralles F; Gil-Perotín S; Navarré A; Boscá I; Coret F; Casanova B
    J Neurol; 2018 Jul; 265(7):1690-1697. PubMed ID: 29785523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
    Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
    Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy and safety of Zytux
    Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
    Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.